文献速递骨质疏松与代谢性骨病创伤骨科

AGN1局部骨增强术治疗绝经后骨质疏松女性股骨近端骨丢失可提高髋部骨密度与强度

Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort study.
PubMed 文献 · Osteoporos Int · 2019-12-04

这项首次人体前瞻性队列研究纳入12例绝经后骨质疏松女性(股骨颈T值≤-2.5,年龄56-89岁),对左侧股骨行AGN1局部骨增强术(LOEP),右侧为对照,随访5-7年。结果显示治疗侧股骨颈aBMD较对照持续显著增加,有限元分析估计的股骨强度亦显著提高,AGN1在24周内几乎完全被骨替代,5-7年时完全吸收并与周围骨整合,无手术或器械相关严重不良事件。

要点

  • AGN1 LOEP可快速且持久地增加股骨颈aBMD,5-7年时仍较对照高58±27%。
  • FEA估计的股骨强度在12周、24周和5-7年分别增加41%、37%和22%。
  • AGN1在24周内几乎完全吸收并被新骨替代,5-7年时完全吸收并与周围骨整合。

核心结论

  • AGN1 LOEP治疗绝经后骨质疏松女性股骨可快速、持久地增加aBMD和股骨强度,支持其用于髋部骨折高风险骨质疏松患者并需进一步临床研究。

研究设计与样本

  • 首次人体前瞻性队列研究,纳入12例绝经后骨质疏松女性(股骨颈T值≤-2.5),年龄56至89岁,左股骨行AGN1 LOEP,右股骨为未治疗对照,随访5-7年。

主要发现

  • 治疗侧股骨颈aBMD较对照在12周、24周和5-7年分别增加68±22%、59±24%和58±27%(p<0.001,所有时间点)。
  • FEA估计的股骨强度在12周、24周和5-7年分别增加41%、37%和22%(p<0.01,所有时间点)。
  • X线和CT定性分析显示AGN1在24周内几乎完全吸收并被骨替代,5-7年时完全吸收并与周围小梁骨和皮质骨整合。
  • 未发生手术或器械相关严重不良事件(SAEs)。

临床怎么用

  • 对于髋部骨折高风险的绝经后骨质疏松女性,AGN1 LOEP可能作为一种微创局部增强手段,快速且持久提高股骨近端骨密度和强度。

局限性

  • 首次人体研究样本量小(12例),需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This first-in-human study of AGN1 LOEP demonstrated that this minimally-invasive treatment durably increased aBMD in femurs of osteoporotic postmenopausal women. AGN1 resorption was coupled with new bone formation by 12 weeks and that new bone was maintained for at least 5-7 years resulting in substantially increased FEA-estimated femoral strength. INTRODUCTION: This first-in-human study evaluated feasibility, safety, and in vivo response to treating proximal femurs of postmenopausal osteoporotic women with a minimally-invasive local osteo-enhancement procedure (LOEP) to inject a resorbable triphasic osteoconductive implant material (AGN1). METHODS: This prospective cohort study enrolled 12 postmenopausal osteoporotic (femoral neck T-score ≤ - 2.5) women aged 56 to 89 years. AGN1 LOEP was performed on left femurs; right femurs were untreated controls. Subjects were followed-up for 5-7 years. Outcomes included adverse events, proximal femur areal bone mineral density (aBMD), AGN1 resorption, and replacement with bone by X-ray and CT, and finite element analysis (FEA) estimated hip strength. RESULTS: Baseline treated and control femoral neck aBMD was equivalent. Treated femoral neck aBMD increased by 68 ± 22%, 59 ± 24%, and 58 ± 27% over control at 12 and 24 weeks and 5-7 years, respectively (p < 0.001, all time points). Using conservative assumptions, FEA-estimated femoral strength increased by 41%, 37%, and 22% at 12 and 24 weeks and 5-7 years, respectively (p < 0.01, all time points). Qualitative analysis of X-ray and CT scans demonstrated that AGN1 resorption and replacement with bone was nearly complete by 24 weeks. By 5-7 years, AGN1 appeared to be fully resorbed and replaced with bone integrated with surrounding trabecular and cortical bone. No procedure- or device-related serious adverse events (SAEs) occurred. CONCLUSIONS: Treating femurs of postmenopausal osteoporotic women with AGN1 LOEP results in a rapid, durable increase in aBMD and femoral strength. These results support the use and further clinical study of this approach in osteoporotic patients at high risk of hip fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Howe JG, Hill RS, Stroncek JD, et al. Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort study. Osteoporos Int. 2019. PMID: 31802158. doi:10.1007/s00198-019-05230-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。